ACRX News and Press, AcelRx Pharmaceuticals Inc. From 05/10/22

AcelRx Pharma (NASDAQ:ACRX -5.6%) said on Tuesday that a study found that its drug, sufentanil sublingual tablet 30 mcg, lowered the opioid dose required by patients in the post-anesthesia care unit by more than five-fold compared to standard intravenous opioid administration. The compan...

AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia PR Newswire Study found that...

AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 PR Newswire HAYWARD, Calif. , May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it wil...

Key Opinion Leaders participating will be Stuart Goldstein, MD, Cincinnati Children’s Hospital and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center Webinar to be held Wednesday, ...

Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 PR Newswire HAYWARD, Calif. , April 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: A...

AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 PR Newswire HAYWARD, Calif. , April 21, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("A...

AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures PR Newswire Study results show higher rates of successful procedure completion and higher pat...

AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit PR Newswire Study results demonstrate that nafamostat had similar efficacy as citrate, while ...

ACRX 4q21 revenue numbers confused many readers of the earnings release. Revenue numbers are better – and more insightful – than they appear at first glance. Nonetheless, the strong market sell-off seems justified due to further decreasing earnings visibility and str...

AcelRx Pharmaceuticals (ACRX -15.1%) was downgraded by H.C. Wainwright to Neutral from Buy without a price target following its Q4 results last week. The company lost -20.64% on March 11, the day after its Q4 results on March 10 post market. Analyst Ed Arce said the company reported...